US FDA urges MRI firms to re-think contrast agent labelling
This article was originally published in RAJ Devices
Executive Summary
Leading manufacturers of imaging agents have once again been asked by the US Food and Drug Administration to warn customers of the potential risks of using gadolinium-based MRI contrast agents in patients with severe kidney disease1,2.